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Abstract
Cancer stem cells (CSCs) are tumor subpopulations driving disease development, progression, relapse and therapy
resistance, and their targeting ensures tumor eradication. CSCs display heterogeneous replication stress (RS), but the
functionality/relevance of the RS response (RSR) centered on the ATR-CHK1 axis is debated. Here, we show that the RSR
is efficient in primary CSCs from colorectal cancer (CRC-SCs), and describe unique roles for PARP1 and MRE11/RAD51.
First, we demonstrated that PARP1 is upregulated in CRC-SCs resistant to several replication poisons and RSR inhibitors
(RSRi). In these cells, PARP1 modulates replication fork speed resulting in low constitutive RS. Second, we showed that
MRE11 and RAD51 cooperate in the genoprotection and mitosis execution of PARP1-upregulated CRC-SCs. These roles
represent therapeutic vulnerabilities for CSCs. Indeed, PARP1i sensitized CRC-SCs to ATRi/CHK1i, inducing replication
catastrophe, and prevented the development of resistance to CHK1i. Also, MRE11i+ RAD51i selectively killed PARP1-
upregulated CRC-SCs via mitotic catastrophe. These results provide the rationale for biomarker-driven clinical trials in CRC
using distinct RSRi combinations.
Introduction
Most human solid tumors, including colorectal cancer (CRC),
are characterized by substantial interpatient and intratumor
heterogeneity at genetic, epigenetic, transcriptional and/or
phenotypic levels, representing a major obstacle to cancer
treatment and patient survival [1–3]. A large body of evidence
also indicates that tumors have a high cellular complexity
often manifested with a hierarchical organization resembling
that of the normal tissue [3, 4]. Indeed, marker-driven isola-
tion, in vivo xenotransplantation, cell-ablation, lineage track-
ing, and single-cell genomics studies have revealed the
presence, in CRC, of a mix of malignant cells with different
degree of differentiation, maintained by a subpopulation of
stem cell-like cells, known as cancer-stem cells (CSCs) [5–
13]. In these studies, CSCs were detected in all steps of CRC
development and shown to drive disease initiation, progres-
sion and dissemination.
The stemness-like properties of CSCs (i.e., self-renewal
and multilineage differentiation potential), together with
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their unique therapeutic resistance, make these cells a major
source of tumor heterogeneity and the culprit of treatment
failure and tumor relapse [3, 14]. The specific targeting of
CSCs is advocated to eradicate tumors, but other layers of
complexity are emerging. It is now clear that cell types and
states in tumors are dynamic features [15, 16]. Moreover,
CSCs are reported to evolve both during disease progres-
sion and in response to therapy [17]. This explains the high
heterogeneity in phenotypic markers, proliferation rate,
tumorigenic/metastatic potential, karyotype, and treatment
responsiveness observed across CSCs derived from CRC
[18–24].
CSC heterogeneity represents a novel therapeutic chal-
lenge. Indeed, CSCs are endowed with a very robust DNA
damage response (DDR), which drives resistance to geno-
toxic stress, but also constitutes a unique therapeutic vul-
nerability. However, such strong DDR in CSCs is reported
to arise from multiple, non-mutually exclusive mechanisms,
including enhanced DNA damage repair efficiency, DNA
damage tolerance, antioxidant defenses as well as DDR
signaling overactivation, apoptosis deregulation or senes-
cence evasion (reviewed in [25]). Consequently, the tar-
geting of one such unique CSC feature can be ineffective
against some CSC subsets, and resistance can also emerge.
So, it is urgent to reconstruct all the branches of the DDR in
CSCs, and patient-derived experimental models capturing
tumor genetic and phenotypic diversity can be suitably used
to this aim [26].
One specialized branch of the DDR is dedicated to the
management of replication stress (RS), so-called RS
response (RSR) [27, 28]. RS is a form of genetic instability
originating from the deregulation of the DNA replication
process by endogenous or exogenous factors encompassing
oncogenes, such as HRAS, MYC and CCNE1, or conven-
tional anti-CRC chemotherapeutics, such as 5-FU, irinote-
can and oxaliplatin [29–31]. These perturbations induce
transient slowing or stalling of replication forks, resulting in
the generation of long stretches of single-stranded DNA
(ssDNA) at replication-fork junctions [28, 32]. The loading
of ssDNA by the replication protein A (RPA) complex
triggers the ATR-CHK1 axis of the RSR that arrests DNA
replication and cell cycle progression through the activation
of the intra-S checkpoint, also known as DNA replication
checkpoint [28]. This limits further RS generation, repli-
cation factor exhaustion, and untimely mitotic entry [33],
culminating either in the resolution/tolerance of DNA
lesions or in the demise/senescence of cells too severely
perturbed [28, 34, 35].
RS is frequently found in pre-cancerous lesions [36–38]
and in established tumors [39, 40], but its levels appear
heterogeneous in CSCs [21, 41]. Moreover, the mechanisms
of RSR in CSCs have been poorly investigated so far. At
this regard, the relevance of the RSR in CSCs is a matter of
contentious [21, 41–43], and the actual functionality of the
RSR in CSCs has been recently questioned [42]. Also, RSR
abrogation variably affects CSC survival [27], as we pre-
viously showed in a panel of CRC patient-derived tumor-
spheres enriched for CSCs (CRC-SCs) treated with ATR
or CHK1 inhibitors [21]. Finally, very few studies have
specifically dealt with the development of resistance to RSR
inhibitors in CSCs. Elucidating these issues could guide not
only the design of specific prevention or rescue resistance
therapies but also the identification of novel therapeutic
vulnerabilities of CSCs.
Here, we demonstrated that the RSR in primary CRC-
SCs is highly efficient and relies on the cooperation
between the ATR-CHK1 axis and DDR players PARP1,
RAD51 and/or MRE11. Building on these findings, we
developed optimal, resistance-proof protocols targeting all
CRC-SC subsets of our panel regardless of their genetic or
ploidy profile.
Results
Impact of prolonged inhibition of the ATR-CHK1 axis
on colorectal cancer stem cells (CRC-SCs)
We previously showed that two-third of tumors contain CRC-
SCs sensitive to the abrogation of the ATR-CHK1 axis of the
RSR [21]. Among them, we can distinguish CRC-SCs
hypersensitive or moderately sensitive to the inhibition
of CHK1 by prexasertib (hereafter referred to as CHK1i)
(Supplementary Fig. S1a). To investigate the RSR in CSCs,
we first selected two functional subtypes of CRC-SCs: the
KRAS wild-type #1 (CHK1i hypersensitive), and the KRAS
mutated #19 (CHK1i moderately sensitive) [21]. These cells
were relieved from their dependence on the ATR-CHK1
cascade by subjecting them to several consecutive rounds of
treatments with CHK1i, starting from the IC50/2 value and
gradually increasing the dose to 1 μM (Fig. 1a). Through this
strategy, we favored the acquisition of resistance to CHK1i in
both CRC-SCs, hereafter defined neo-resistant (neoR).
CHK1i resistance was confirmed by a very low impact of
CHK1i on survival (#1neoR IC50= 2.9 μM; #19neoR IC50=
4.1 μM), clonogenic/stemness potential and CD44v6+ stem-
like fraction (Fig. 1b, c; Supplementary Fig. S1b, c). The
concurrent administration of calcium channel blocker ver-
apamil did not revert CHK1i resistance, ruling out a drug
efflux phenomenon (Supplementary Fig. S1d). A drug-
screening with 25 DDR targeting/triggering agents, includ-
ing replication poisons commonly used to treat CRC in
clinical practice, revealed that neoR-CRC-SCs were sig-
nificantly more resistant than their sensitive counterparts
(hereafter referred to as SENS) to the CHK1 inhibitor rabu-
sertib and to the ATR inhibitors VE-821 and berzosertib
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(Fig. 1d, e; Supplementary Fig. S1e, f). On the contrary, no
differences were found in CRC-SC response to inhibitors of
the other DDR kinases ATM, CHK2 and DNA-PK, which
were all less effective than ATR/CHK1 inhibitors (Fig. 1e;
Supplementary Fig. S1f). Along with an insensitivity to ATR/
CHK1 inhibition, neoR-CRC-SCs demonstrated a significant
higher resistance than SENS-CRC-SCs to the clinically-
relevant replication poisons irinotecan and, to a lesser extent,
5-FU and oxaliplatin (Fig. 1d, e; Supplementary Fig. S1e, f;
Supplementary Tables S1, S2). This difference could be
ascribed to the high sensitivity of SENS-CRC-SCs to irino-
tecan. Moreover, at least one neoR-CRC-SCs show increased
resistance to most (but not all) RS-inducing agents, including
gemcitabine, cisplatin, camptothecin and adavosertib (Fig. 1e;
Supplementary Fig. S2), indicating an increased capability to
resolve/tolerate severe RS.
Altogether, these findings demonstrate that prolonged
impairment of the RSR by CHK1i results in increased
resistance of CRC-SCs to clinically-relevant replication
poisons and to inhibitors of the ATR-CHK1 cascade.
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Replication stress response is functional and
efficient in CRC-SCs
The RSR status in CSCs is debated [27, 41–43]. There-
fore, we exploited the newly-generated neoR/SENS pairs
to investigate the RSR in CRC-SCs. We first explored
RSR activity in CRC-SCs exposed to exogenous RS
(Fig. 2a–c). Specifically, we performed a protocol of
sequential administration of the RS inducer hydroxyurea
(HU) and, after drug wash, of nocodazole (N), known as
HU+N protocol [42, 44, 45] (Fig. 2a, b). In such assay,
RSR-proficient cells can resolve severe RS, progressing in
the cell cycle and arresting in metaphase, while cells with
impaired RSR get stuck in the S-phase. We demonstrated
that both neoR-CRC-SCs and SENS-CRC-SCs display an
efficient RSR, as shown by low percentages of S-phase
cells coupled with a huge increase in mitoses (Fig. 2b;
Supplementary Fig. S3a) and absent DNA damage in most
cells with replicated DNA (Supplementary Fig. S3b).
Corroborating RSR proficiency, neoR-CRC-SCs activate
the intra-S checkpoint, as revealed by the high accumu-
lation of S-phase cells and DNA lesions after treatment
with gemcitabine (Fig. 2c; Supplementary Fig. S3c).
We then explored the RSR in CRC-SCs not exposed to
exogenous stress. We observed that untreated neoR-CRC-
SCs display a significant decrease in constitutive RS com-
pared to their SENS counterparts, manifested with a lower
fraction of cells positive to pRPA32 or displaying parental
ssDNA, two RS markers (Fig. 2d). Contrarily to their SENS
counterparts [21], neoR-CRC-SCs treated with CHK1i did
not experience severe RS, as shown by the low increase in
the level of the RS markers pRPA32, pATM, and γH2AX
(Fig. 2d, e; Supplementary Fig. S3d), and were not affected
in their cell cycle progression (Fig. 2c; Supplementary Fig.
S3c, e). Thus, in untreated conditions, low constitutive RS
levels in neoR-CRC-SC make the ATR-CHK1 axis dis-
pensable for survival. Accordingly, multiple agents boost-
ing RS sensitized neoR-CRC-SCs to CHK1 and/or ATR
inhibitors (Supplementary Fig. S3f–h).
Collectively, these observations demonstrate that the
RSR is functional and efficient in CRC-SCs, but becomes
dispensable for survival in CRC-SCs with low
constitutive RS.
PARP1 is upregulated and adjusts replication fork
speed in resistant CRC-SCs
To uncover unique mechanisms in the RSR of neoR-CRC-
SCs, we performed targeted DNA sequencing analyses of
a set of DDR-related genes in neoR/SENS pairs. None-
theless, we detected no significant changes in the genetic
background of neoR-CRC-SCs vs. SENS-CRC-SCs, and
no commonly acquired/lost mutations in neoR-CRC-SCs
(Fig. 3a; Supplementary Table S3). On the contrary, we
revealed an increase in constitutive protein levels of
PARP1 in untreated neoR-CRC-SCs compared to their
SENS counterparts (Fig. 3b; Supplementary Fig. S4a).
Reportedly, PARP1 contributes to both DNA replica-
tion and DNA damage repair [46]. To explore the func-
tional relevance of PARP1, we used the pharmacological
inhibitors of PARP1/2 (hereafter referred to as PARP1i)
olaparib and talazoparib assessing the response to RS.
Through the HU+N assay, we observed correct S-phase
progression, massive mitosis accumulation and low DNA
damage persistence in both neoR-CRC-SCs and SENS-
CRC-SCs challenged with HU and then coexposed to
nocodazole and PARP1i (Fig. 3c; Supplementary Fig.
S4b). On the contrary, CHK1i decreased the efficiency of
neoR-/SENS-CRC-SCs to respond to severe RS by HU,
an effect not modified by concurrent PARP1 inhibition
(Fig. 3c; Supplementary Fig. S4b). This indicates that the
ATR-CHK1 axis but not PARP1 is crucial in resolving
severe RS induced by replication poisons. Intriguingly,
Fig. 1 Effects of prolonged abrogation of the ATR-CHK1 axis in
CRC-SCs. a Scheme of the experimental protocol used for the gen-
eration of neoR-CRC-SCs. For further details, see Materials and
Methods. CHK1i refers to prexasertib, a preferential inhibitor
of CHK1 and to a lesser extent CHK2. b Cell proliferation/viability of
neoR-CRC-SCs vs. SENS-CRC-SCs left untreated or treated for 72 h
with the indicated concentration of CHK1i, as assessed by CellTiter-
Glo® assay. Dose-response curves were calculated from the individual
dose-response curves (each coming from an independent experiment)
reported in Supplementary Fig. S1c. Results are expressed as means ±
SEM, with number of independent experiments (n) for each group
also reported. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the
corresponding neoR-CRC-SCs treated with the same dose (unpaired
t-test with or without Welch’s correction). c Clonogenic survival of
neoR-SENS-CRC-SCs vs. SENS-CRC-SCs left untreated or treated
for 24 h with CHK1i, as indicated. Representative clonogenic assay
images and quantitative data are reported. Results are expressed as
means ± SEM and individual data points (n= 3 for #1SENS; n= 4 for
#1neoR, #19SENS and #19neoR). *P < 0.05, **P < 0.01, ***P < 0.001
compared to untreated conditions for each CRC-SC (one-way
ANOVA and Bonferroni or Dunnett T3 post-hoc test). d Dose-
response curves of neoR-CRC-SCs vs. SENS-CRC-SCs left untreated
or exposed for 72 h to ATR or CHK1 inhibitors or irinotecan as
representative RS inducer. Proliferation/viability was assessed by
CellTiter-Glo® assay. Results are means ± SEM calculated from indi-
vidual dose-response curves of Supplementary Fig. S1e. The n for
each group is reported. *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired
t-test with or without Welch’s correction) compared to the corre-
sponding neoR-CRC-SCs treated with the same dose. e Heatmap
showing the differential sensitivity of neoR/SENS pairs to DDR
inhibitors or activators. The values refer to log2 of the ratio of per-
centage of viable cells of neoR-CRC-SCs vs. SENS-CRC-SCs, cal-
culated for each dose using data from dose-response curves of Fig. 1b,
d, and Supplementary Figs. S1, S2. IC50 values for drugs differentially
affecting neoR-CRC-SCs and SENS-CRC-SCs are in Supplementary
Table S1, while all log2 values are in Supplementary Table S2.
TOPO, topoisomerase. All significant P values are shown in Supple-
mentary Table S4. Supplementary figures associated: Supplementary
Figs. S1 and S2.
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RSR impairment by CHK1i was more pronounced in
SENS-CRC-SCs than in neoR-CRC-SCs (Fig. 3c; Sup-
plementary Fig. S4b), pointing to the emergence of
additional mechanisms handling RS in neoR-CRC-SCs.
Next, we analyzed the role of PARP1 in DNA replication
of CRC-SCs not exposed to exogenous stress. By flow
cytometry, we revealed that, in neoR-CRC-SCs, PARP1i
monotherapy did not significantly increase the levels of
γH2AX in S-phase, a marker of RS fork breakage (Fig. 3d).
On the contrary the concurrent administration of CHK1i
and PARP1i boosted RS in neoR-CRC-SCs (Fig. 3d).
Likewise, the CHK1i+ PARP1i regimen augmented the
levels of pRPA32 and γH2AX in immunofluorescence and
western-blot (Fig. 3e; Supplementary Fig. S4c).
To explore DNA replication, we performed DNA fiber
assay, allowing for visualizing/monitoring the dynamics
of individual DNA replication forks [47]. In untreated
conditions, we observed a slight but significant decrease
of the replication track length in neoR-CRC-SCs vs.
SENS-CRC-SCs, a sign of decelerated fork progression
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(by fork reversal [48]) or enhanced nuclease degradation
at the replication fork (Fig. 3f). Intriguingly, CHK1i
provoked nascent strand shortening in SENS-CRC-SCs
but did not significantly modulate fork progression in
neoR-CRC-SCs, which is in line with RS induction in the
former. On the contrary, PARP1 inhibition led to a dra-
matic increase in DNA replication track length in neoR-
CRC-SCs, a sign of accelerated DNA replication and
increased fork progression speed, while did not affect
track length of SENS-CRC-SCs (Fig. 3f). In line with the
severe RS induction shown before, CHK1i+ PARP1i
diminished DNA replication track length also in neoR-
CRC-SCs. These observations reveal a unique role of
PARP1 in modulating fork speed progression in neoR-
CRC-SCs.
To further explore replication fork integrity, we detected
nascent ssDNA, a marker of DNA degradation at active
replicating forks [49]. We observed low/absent nascent
ssDNA in untreated and PARP1i-treated neoR-CRC-SCs,
implying that PARP1 acts by modulating fork progression
speed rather than nuclease degradation at replicating forks
(Fig. 3g). Nascent ssDNA levels significantly increased
only upon CHK1i+ PARP1i (Fig. 3g), confirming that
PARP1 inhibition boosts RS in neoR-CRC-SCs only when
combined with ATRi/CHK1i.
Altogether, these findings demonstrate that PARP1 acts
by adjusting replication fork speed in neoR-CRC-SCs.
PARP1 inhibition reverts CSC resistance to ATR-
CHK1 inhibitors inducing replication catastrophe
We then assessed the impact of PARP1 upregulation on
CSC survival. In line with drug-screening results, we con-
firmed that PARP1i alone did not affect neoR-CRC-SC
survival (Fig. 4a). However, we showed that the inhibition
of PARP1 significantly sensitizes neoR-CRC-SCs to
CHK1i, exerting a synergistic effect (Fig. 4a, b; Supple-
mentary Fig. S5a). Interestingly, CHK1i sensitization was
observed for olaparib and talazoparib, which trap PARP1 on
damaged DNA (PARP1 trappers [50, 51]), but not for the
weak PARP1 trapper veliparib (Fig. 4c). Also, the specific
PARP2i UPF 1069 did not increase CHK1i sensitivity
(Fig. 4d), proving that such effect is PARP1-dependent.
This evidence suggests that neoR-CRC-SC killing by
CHK1i+ PARP1i occurs through replication catastrophe
[33].
Importantly, the clonogenic survival of neoR-CRC-SCs
was dramatically affected by CHK1i+ PARP1i but not by
CHK1i or PARP1i monotherapies (Fig. 5a; Supplementary
Fig. S5b), confirming that CHK1i+ PARP1i efficiently
targets the CSC compartment. Consistently, CHK1i+ ola-
parib significantly impaired the in vivo growth of neoR-
CRC-SCs xenografted into the flank of immunodeficient
NSG mice, while CHK1i/PARP1i monotherapies had no
in vivo antitumor effect (Fig. 5b). Using our characterized
CRC-SC panel (Supplementary Fig. S1a), we revealed that
CRC-SC hypersensitive to CHK1i (SENSHIGH) display
lower basal protein levels of PARP1 than CRC-SCs mod-
erately sensitive to CHK1i (SENSMED) or innately resistant
to CHK1i (innR) (Fig. 5c). Notably, PARP1i conferred
sensitization to CHK1i also in innR-CRC-SCs, confirming
the relevance of PARP1 in driving CRC-SC resistance to
CHK1i (Fig. 5d).
These results demonstrate that PARP1 inhibition effi-
ciently sensitizes former resistant CRC-SCs to CHK1i, both
in vitro and in vivo, by inducing replication catastrophe.
Targeting PARP1 prevents the acquisition of CSC
resistance to ATR/CHK1 inhibitors
To make our results relevant for the clinic, we exploited
the identified mechanism of resistance to CHK1i based on
PARP1 upregulation as a means to prevent the acquisition
of CHK1i resistance. To this aim, we added PARP1i
during the neoR generation protocol (Supplementary Fig.
S6a). Our rationale was to deplete the fraction of CRC-
SCs with increased PARP1 levels once selected by
CHK1i. Corroborating our hypothesis, PARP1i avoided
the acquisition of resistance to CHK1i, leading (at
least for talazoparib in most experiments) to the near-to-
complete depletion of SENS-CRC-SCs (Fig. 6a;
Fig. 2 RSR is functional and efficient in CRC-SCs. a–c Evaluation
of RSR proficiency in neoR/SENS-CRC-SCs subjected to exogenous
replication stress (RS) as illustrated in the scheme in a. Specifically,
cells were left untreated or either sequentially exposed to 1 mM
hydroxyurea (HU) and, after drug washout, 1 µM nocodazole (N) (a,
b; the so-called HU+N assay, see Materials and Methods), or treated
for 24 h with 100 nM gemcitabine (GEM) or prexasertib (CHK1i) (a,
c). Flow-cytometric cell cycle profiles upon staining with a DNA
intercalant (DAPI) alone (c) or together with an anti-pH3 antibody (b)
and quantitative data (c; means ± SEM from 6 independent experi-
ments) are reported. In b, mitotic (pH3+) cells are in red. See also
Supplementary Fig. S3a–c. *P < 0.05, **P < 0.01, ***P < 0.001 (one-
way ANOVA and Dunnett T3 post-hoc test) compared to untreated
conditions. d Immunofluorescence analysis in neoR-CRC-SCs and
SENS-CRC-SCs left untreated or exposed for 24 h to 100 nM CHK1i
and stained with an anti-pRPA32 antibody (top) or incubated with 10
μM IdU prior to anti-BrdU staining (bottom). Representative images
and quantification of pRPA32+ cells and cells with parental ssDNA
are reported. Results are expressed as means ± SEM and individual
data points. Numbers refer to the number of independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.001 (unpaired t-test with or without
Welch’s correction) as indicated. In the bottom part, statistical analysis
was performed only in the histogram on the right. e Western-blot
analysis in #1SENS-CRC-SCs and #1neoR-CRC-SCs treated or not
with 100 nM CHK1i using the depicted antibodies (nucleolin as
loading control). #1neoRa and #1neoRb correspond to cells collected
after 12 and 17 weeks during CHK1i resistance generation. See also
Materials and Methods and Supplementary Fig. S3d. All significant P
values are shown in Supplementary Table S4. Supplementary figures
associated: Supplementary Fig. S3.
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Supplementary Fig. S6b). Intriguingly, CHK1i+ PARP1i
decreased cell survival in SENS-CRC-SCs from the first
cotreatment round. In line with this observation, the
combination of sublethal doses of CHK1i and PARP1i
efficiently killed SENS-CRC-SCs (Fig. 6b), also impair-
ing clonogenicity (Fig. 6c; Supplementary Fig. S6c). We
surmise that this sensitization is due to a further increase
in RS by PARP1i, resulting in higher dependence on the
ATR-CHK1 cascade. Accordingly, the administration of
RS inducers sensitized SENS-CRC-SCs to sublethal doses
of CHK1i (Supplementary Fig. S6d).
To further validate the role of PARP1 in resistance to
ATRi/CHK1i, we generated neoR-CRC-SCs from 6 addi-
tional CRC-SCs with moderate/high sensitivity to CHK1i.
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We revealed that all SENS-CRC-SCs developed resistance
to CHK1i, but SENSMED-CRC-SCs acquired resistance
more rapidly than SENSHIGH-CRC-SCs (Fig. 6d; Supple-
mentary Fig. S6e), presumably for their higher PARP1
levels. Taking advantage of these novel SENS/neoR pairs,
we confirmed that PARP1i prevents the generation of
resistance to CHK1i, sensitizing CRC-SCs to this agent
(Fig. 6e, f; Supplementary Fig. S6f).
In conclusion, PARP1 inhibition not only sensitizes to,
but also prevents the acquisition of resistance to CHK1i.
Combined inhibition of MRE11 and RAD51 kills
PARP1-upregulating CSCs by inducing mitotic
catastrophe
To further extend the clinical potential of our results, we
reasoned that the role of PARP1 in the RSR of neoR-CRC-
SCs could make these cells vulnerable to the inhibition of
other fork remodeling/stabilizing players, focusing on the
druggable players MRE11 and RAD51 [52]. We observed
that pharmacological inhibitors of MRE11 (by mirin) or
RAD51 (by B02) were ineffective in depleting neoR-CRC-
SCs (Fig. 7a; Supplementary Fig. S7a). On the contrary, the
MRE11i+ RAD51i regimen was effective against
#19neoR-CRC-SCs and (to a lesser extent) #1neoR-CRC-
SCs (Fig. 7a; Supplementary Fig. S7a, b). Moreover,
MRE11i+ RAD51i affected the clonogenic potential of
neoR-CRC-SCs (Fig. 7b; Supplementary Fig. S7c) and the
survival of innR-CRC-SCs and additional neoR-CRC-SCs
(Fig. 7c; Supplementary Fig. S7d). This indicates effective
targeting of the CSC compartment by MRE11i+ RAD51i
and a common dependence on the joint activities of MRE11
and RAD51 in CHK1i-resistant cells. Of note, SENSMED-
CRC-SCs were more efficiently targeted by MRE11i+
RAD51i than SENSHIGH-CRC-SCs (Supplementary Fig.
S7e), possibly due to higher PARP1 levels. These obser-
vations indicate that the combined activities of MRE11 and
RAD51 becomes particularly relevant for CRC-SCs in a
PARP1-upregulated context.
To elucidate the mechanisms of cell death by MRE11i+
RAD51i, we investigated the impact of MRE11 and RAD51
on the RSR of neoR-CRC-SCs. By HU+N assay, we
found that MRE11i+ RAD51i makes the RSR partially
ineffective in neoR-CRC-SCs subjected to exogenous RS
(Fig. 7d), suggesting that the cooperation between MRE11
and RAD51 can contribute to the RSR under severe RS.
However, we observed that the inhibition of MRE11/
RAD51, alone or in combination, did not markedly increase
the level of RS in neoR-CRC-SCs (Fig. 7e; Supplementary
Fig. S7f). Intriguingly, MRE11i+ RAD51i did not affect S-
phase progression, but induced a significant accumulation
of metaphases (pH3+) (Fig. 7f; Supplementary Fig. S7g), an
effect particularly evident in #19neoR and observable to a
lesser extent with MRE11i. Accordingly, the concurrent
inhibition of MRE11 and RAD51 impaired correct mitosis
orchestration in neoR-CRC-SCs leading to accumulation of
aberrant metaphases activating the spindle assembly
checkpoint (SAC) [53] as shown by kinetochore localiza-
tion of BUBR1 (BUBR1+pH3+ cells), along with an almost
Fig. 3 PARP1 is upregulated and modulates DNA replication
speed in neoR-CRC-SCs. a Oncoprint of mutations for 61 DDR-
related genes in neoR-CRC-SCs and SENS-CRC-SCs identified by
deep sequencing. Only mutations included in COSMIC (“C”; http://ca
ncer.sanger.ac.uk/cosmic) and/or annotated as (likely) oncogenic (dark
gray squares) in the oncoKB database (https://oncokb.org/) are
reported. Mutated gene number and allelic frequencies per CRC-SC
are shown. Full gene list is in Supplementary Table S3. b Western-blot
analysis in neoR-CRC-SCs and SENS-CRC-SCs left untreated or
administrated for 6 h or 24 h with 100 nM prexasertib (CHK1i) and
then stained with antibodies recognizing PARP1 and β-Actin or
β-Tubulin (to ensure equal lane loading). cPARP1, cleaved PARP1.
c Flow cytometry analysis in one representative CRC-SC pair
(#1SENS/neoR) left untreated or sequentially treated with 1 mM
hydroxyurea (HU) and, after drug washout, with 1 µM nocodazole (N)
alone or together with CHK1i and/or PARP1i (talazoparib, TZ) (the
HU+N assay, see Fig. 2a). Cell cycle profiles for #1neoR and
quantification of S- and G2/M-phase cells for #1neoR and #1SENS are
shown. Mitotic (pH3+) cells are in red. Results are expressed as means
± SEM and individual data points of 4 (#1SENS) or 5 (#1neoR)
independent experiments. Cell cycle profiles of #1SENS are in Sup-
plementary Fig. S4b. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way
ANOVA and Bonferroni or Dunnett T3 post-hoc test) compared to
HU+N-treated conditions. #P < 0.05, ##P < 0.01, ###P < 0.001
(unpaired t-test) compared to SENS-CRC-SCs. d, e Flow cytometry
and immunoblot analysis of RS markers in neoR-CRC-SCs left
untreated or treated with CHK1i and/or olaparib (O) or TZ (T) for 24 h
(d) or 72 h (e) and stained with antibodies recognizing γH2AX,
pRPA32, RPA32 and/or DAPI. Cell cycle profiles and quantification
of γH2AX+ S-phase cells are reported in d. Results are means ± SEM
of 5 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001
(one-way ANOVA and Bonferroni post-hoc test) as indicated (d). In
e, β-Tubulin was used to ensure equal lane loading. See also Sup-
plementary Fig. S4c. f DNA fiber assay in representative neoR/SENS-
CRC-SCs (#19) left untreated or treated for 6 h with CHK1i and/or TZ
and labeled with 250 µM IdU for the last 30 min. Representative DNA
fiber images and dot-plots of IdU-labeled tract lengths for only
untreated cells (left) or all conditions (right) are shown. Number of
well-isolated DNA fibers per condition is reported. Data were pooled
from four (left) and two (center and right) independent experiments
(see Materials and Methods), and shown as box-plots with means
and individual data points. *P < 0.05, **P < 0.01, ***P < 0.001,
Mann–Whitney test for the comparison neoR-CRC-SCs vs. SENS-
CRC-SCs (left), and Kruskal–Wallis ANOVA followed by Dunn’s
post-hoc test for comparisons within neoR or SENS groups (center/
right). g Immunofluorescence detection of nascent ssDNA in neoR-
CRC-SCs left untreated or exposed to CHK1i and/or TZ for 6 h,
labeled for the last 30 min of the treatment with 250 µM IdU, and
finally stained with an anti-BrdU antibody. Representative images and
quantification of cells displaying nascent strands (BrdU+) are shown.
Data were pooled from two independent experiments and shown as
box-plots with means and individual data points. Number of analyzed
cells per condition is reported. *P < 0.05, **P < 0.01, ***P < 0.001
(Kruskal–Wallis ANOVA followed by Dunn’s post-hoc test). Dose
range in c–g: 100–200 nM CHK1i, 5 µM OLA, 300–500 nM TZ; a.u.
arbitrary units. All significant P values are shown in Supplementary
Table S4. Supplementary figures associated: Supplementary Fig. S4.
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complete depletion of anaphases (Fig. 7g). Mitotic defects
were accompanied by the induction of apoptosis as
demonstrated by the increased incorporation of the vital dye
propidium iodide (Supplementary Fig. S8) coupled to
increased activation of caspase-3 (Fig. 7h) in neoR-CRC-
SCs cotreated with MRE11i and RAD51i. These findings
indicate that MRE11i+RAD51i kills neoR-CRC-SCs by
mitotic catastrophe [54] with a pathway dependent on cas-
pase activity.
In conclusion, we provided evidence of a novel func-
tional interplay between MRE11 and RAD51 in the RSR
and mitosis, which becomes essential, and hence exploi-
table therapeutically, in PARP1-upregulating CRC-SCs.
Discussion
CSC depletion ensures tumor eradication, but the poor
characterization of the mechanisms involved in genomic
stability and drug resistance in CSCs together with their
substantial heterogeneity constitute obstacles to the devel-
opment of effective anti-CSC strategies. Here, we
demonstrated that the RSR is functional in primary CRC-
SCs, as we uncovered mechanistic insights in the RSR,
which we successfully exploited for the design of long-term
effective therapeutic protocols against CRC.
This study provides three major molecular insights with
therapeutic implications. First, the actual functionality of the
RSR in CSCs is a matter of debate. On the one hand, two
studies on patient-derived ovarian cancer organoids and
glioblastoma SCs reported that CSCs efficiently resolve RS
[41, 43], in line with a large body of literature showing
proficient ATR-CHK1 cascade activation by RS inducers in
multiple CSC types [27]. On the other hand, a recent report
on cancer cell lines and primary mammospheres showed an
association between cancer stemness and RSR deficiencies
[42]. Here, we demonstrated that primary CRC-SCs always
display an efficient RSR. Our view to reconcile these results
is that the RSR is specifically impaired in CSCs during
tumor initiation, but a robust RSR is required in CSCs of
established neoplasms endowing them with the capability to
resist or tolerate RS. The evidence that the ATR-CHK1
cascade remains functional in RSR-impaired CSCs [42]
suggests the existence of a hitherto unidentified inhibitory
Fig. 4 PARP1 inhibition sensitizes CRC-SCs to CHK1 inhibitors.
a, b Cell viability (evaluated by CellTiter-Glo® assay) of neoR-CRC-
SCs exposed for 96 h with CHK1i alone or in combination with ola-
parib (OLA) or talazoparib (TZ), as indicated. Results are means ±
SEM and individual data points of 5 (for OLA-treated #1neoR, TZ-
treated #1neoR and OLA-treated #19neoR) or 3 (for TZ-treated
#19neoR) independent experiments. *P < 0.05, **P < 0.01, ***P <
0.001 (one-way ANOVA and Bonferroni or Dunnett T3 post-hoc test)
as reported. In b, synergism is calculated with the Combenefit software
(see Materials and Methods). Similar results were found for doses of
TZ not significantly decreasing neoR-CRC-SC survival when
administered alone (100 and 250 nM; not shown). See also Supple-
mentary Fig. S5a. c, d Cell viability (evaluated by CellTiter-Glo® assay)
of neoR-CRC-SCs left untreated or treated for 96 h with CHK1i alone
or in combination with the indicated doses of PARP1i (veliparib, c) or
PARP2i (UPF 1069, d) inhibitors, as indicated. Data from neoR-CRC-
SCs were pooled. Results are means ± SEM and individual data points
form 3 (c) and 4 (d) independent experiments. No statistical differences
were observed (one-way ANOVA and Bonferroni or Dunnett T3 post-
hoc test). All significant P values are shown in Supplementary
Table S4. Supplementary figures associated: Supplementary Fig. S5.
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mechanism acting specifically during oncogenesis. Eluci-
dating such mechanism and characterizing the RSR status
of tumors at different disease stages are urgent needs for
translating RSR-targeting strategies into the clinics.
Second, we provided evidence of a crucial role of PARP1
in CRC-SCs exhibiting low constitutive RS coupled to high
resistance to (i) replication poisons including the standard
CRC chemotherapeutic irinotecan, and (ii) ATR/CHK1 inhi-
bitors including prexasertib (here dubbed CHK1i) and ber-
zosertib which are under clinic investigation (https://clinica
ltrials.gov). Specifically, we demonstrated that PARP1 is
upregulated in these CSCs, encompassing both neoR-CRC-
SCs and innR-CRC-SCs. We also showed that, although not
directly involved in the response to severe exogenous RS,
PARP1 contributes to basal genetic stability of resistant CRC-
SCs by inducing a global slowdown of replication fork speed.
Reportedly, fork deceleration arises from transient remodeling
of stalled replication forks (so-called fork regression or
reversal), which is modulated by PARP1 [55, 56]. Our
hypothesis is that fork slowdown by PARP1 favors stalled
fork stabilization in resistant CRC-SCs, providing extra-time
to limit ssDNA accumulation and resolve endogenous RS. In
support of this model, fork reversal was previously reported
not only to be associated to active fork slowing upon expo-
sure to replication poisons [57, 58], but also to mitigate
endogenous RS in unperturbed S-phase [46]. Our results also
suggest the existence of a coordination between PARP1 and
the ATR-CHK1 signaling in setting constitutive RS levels in,
and thus conferring therapeutic resistance to, CRC-SCs. We
showed that, when administered alone, PARP1i accelerated
Fig. 5 PARP1 inhibition boosts the in vivo and anticlonogenic
effect of CHK1 inhibitors in CRC-SCs. a Clonogenic survival of
neoR-CRC-SCs left untreated or pretreated for 72 h with 100 nM
prexasertib (CHK1i) alone or together with 5 µM olaparib (OLA) or
300 nM talazoparib (TZ) and then cultivated in drug-free medium as
indicated. Representative images and quantitative data are reported.
Results are means ± SEM and individual data points from 3 indepen-
dent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way
ANOVA and Bonferroni post-hoc test) compared to untreated condi-
tions. See also Supplementary Fig. S5b. b In vivo growth of neoR-
CRC-SCs (#19neoR) xenografted into immunodeficient NSG mice left
untreated or treated with vehicles (Control), 5 mg/kg CHK1i, 50 mg/kg
OLA or 5 mg/kg CHK1i+ 50 mg/kg OLA as indicated (see Materials
and Methods). NSG mice employed per group: Control- and OLA-
groups: 7; CHK1i- and CHK1i+OLA-groups: 8). Tumor size curves
are reported as means ± SEM. Arrows correspond to the first and last
treatment, while line to the treatment period. *P < 0.05, **P < 0.01,
***P < 0.001 (two-way ANOVA and Bonferroni post-hoc test for
multiple time-points) and #P < 0.05, ##P < 0.01, ###P < 0.001
(Kruskal–Wallis ANOVA followed by Dunn’s post-hoc test for the
last time point, vertical lines), as illustrated. c Western-blot analysis in
CRC-SCs intrinsically resistant (innR), or moderately (SENSMED) or
highly (SENSHIGH) sensitive to CHK1i exposed to 100 nM CHK1i for
24 h using antibodies against PARP1 and Cofilin (to ensure equal lane
loading). cPARP1, cleaved PARP1. d Cell viability (evaluated by
CellTiter-Glo® assay) of innR-CRC-SCs treated with CHK1i alone or
in the presence of OLA or TZ as illustrated. Data are reported as
means ± SEM from 7 (on the left) and 8 (on the right) independent
experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA
and Bonferroni or Dunnett T3 post-hoc test) as indicated. All sig-
nificant P values are shown in Supplementary Table S4. Supplemen-
tary figures associated: Supplementary Fig. S5.
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DNA replication in neoR-CRC-SCs but did not significantly
induce RS, resulting in a mild effect on their survival, in line
with a recent study on primary ovarian cancer organoids [43].
On the contrary, coinhibition of PARP1 and CHK1 induced
extensive fork degradation and severe RS in neoR-CRC-SCs,
culminating in cell death due to lethal replication catastrophe
[33] (Fig. 7i). The inhibition of CHK1, albeit not lethal, may
be a contributing RS-inducing factor by promoting replication
fork destabilization [59], which, when combined with fork
deregulation by PARP1i, results in severe RS and CRC-SC
death. It remains to be established whether PARP1 modulates
replication speed in neoR-CRC-SCs by increasing regressed
fork stability [55], preventing untimely fork resumption [55],
regulating fork elongation [60] or acting directly on the DNA
replication process [61].
Importantly, such role of PARP1 can be exploited ther-
apeutically. Indeed, we showed that CHK1i+ PARP1i
decreased both the clonogenicity and in vivo growth of
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CRC-SCs resistant to clinically-relevant replication poisons,
indicating effective targeting of the CSC compartment
responsible for tumor re-growth and expansion [62]. That
said, our results do not exclude that such regimen could also
kill more differentiated cancer cells. Of note, by an original
experimental approach, we demonstrated that the adminis-
tration of PARP1i prevents the acquisition of resistance to
CHK1i in CRC-SCs. This evidence is relevant as in our
setting all SENS-CRC-SCs acquired resistance to CHK1i. It
also supports the therapeutic use of PARP1i in
combinatorial regimens with ATRi/CHK1i, as evaluated in
ongoing clinical trials (https://clinicaltrials.gov).
The third major novelty of this study is the evidence of a
functional link between MRE11 and RAD51 with crucial
implication for genoprotection, mitosis and survival of
PARP1-overexpressing CRC-SCs, including those resistant
to irinotecan and ATRi/CHK1i. Specifically, we showed that
MRE11 and RAD51 cooperate to ensure both an efficient
response to severe RS and mitosis execution. The first action
depends on the roles in the RSR of RAD51, which con-
tributes to stressed replication fork stabilization, regression
and restart in a homologous recombination (HR)-indepen-
dent fashion [57, 63–66], and of MRE11, whose limited
resection activity ensures efficient restart/repriming of stalled
forks [67, 68]. The latter is possibly due to the role of
MRE11 in the G2/M checkpoint and sister chromatid seg-
regation [69–71]. As proof of the relevance of such coor-
dinated function, the combined (but not single) inhibition of
MRE11 and RAD51 effectively kills CRC-SCs displaying
high PARP1 levels via a mitotic catastrophe process sub-
sequent to RSR weakening and defective mitoses (Fig. 7i).
Our hypothesis is that the coordinated activity of MRE11
and RAD51 becomes essential for CRC-SCs downstream of
fork slowdown by PARP1, as it ensures reversed replication
fork protection and timely restart, and, subsequently, accu-
rate mitosis. Thus, beyond representing a mechanism of
resistance and genoprotection [59, 63], fork reversal
could also engender a unique vulnerability exploitable
therapeutically to eradicate specific CRC-SC subsets. Future
investigations will dissect the mechanisms of pathogenicity
of deregulated fork remodeling in CRC-SCs and the link
between RSR and cell division. Irrespective of these
unknowns, our evidence is relevant therapeutically as
MRE11i+RAD51i depletes CRC-SCs without the con-
current presence of endogenous/exogenous RS sources or
exposure to ATR/CHK1 inhibitors.
In conclusion, in this study we contributed to shed light on
the mechanisms of RSR in CSCs as we developed resistance-
proof treatment options to eradicate CRC-SCs based on
the association of specific markers related to the RSR
(i.e., pRPA32 and PARP1). Importantly, these findings can be
rapidly translated into biomarker-driven clinical trials, given
that RSR markers as well as cancer stemness markers can
easily be assessed experimentally in tumor specimens.
Materials and methods
Cell lines and culture conditions
Unless otherwise indicated, cell culture media was provided
by Gibco-Thermo Scientific (Thermo Fisher Scientific,
Waltham, MA), supplements and reagents by Sigma-
Fig. 6 PARP1 inhibition prevents the generation of resistance to
CHK1 inhibitors in CRC-SCs. a Cell viability of SENS-CRC-SCs
left untreated or subjected to consecutive rounds of 72 h-treatment
with prexasertib (CHK1i) alone or in combination with olaparib
(OLA) or talazoparib (TZ) followed by ≥4 days of cultivation in drug-
free medium, as described in Materials and Methods and Supple-
mentary Fig. S6a. After each round of treatment, viable cells were
counted upon Trypan Blue staining. Representative images and
quantitative data of the percentage of viable cells at each treatment
point or at the last time point are shown. Data are expressed as means
± SEM of 3 independent experiments. For the last time points, indi-
vidual data points are also reported. The three individual experiments
are in Supplementary Fig. S6b. *P < 0.05, **P < 0.01, ***P < 0.001
(one-way ANOVA and Bonferroni post-hoc test) compared to
untreated conditions. Doses employed: CHK1i 1-30 nM; OLA 2-7 µM;
TZ 100-500 nM. b Cell viability (assessed by CellTiter-Glo® assay) of
SENS-CRC-SCs left untreated or treated with sublethal doses of
CHK1i and/or PARP1i for 96 h, as indicated. Results are reported as
means ± SEM and individual data points from 5 (on the left) and 3 (on
the right) independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001
(one-way ANOVA and Bonferroni post-hoc test) as indicated. c
Clonogenic survival of SENS-CRC-SCs left untreated or pre-treated
for 72 h with 10 nM CHK1i, 5 µM OLA and/or 300 nM TZ. Quanti-
tative data (#1SENS and #19SENS pooled) are shown. Results are
reported as means ± SEM and individual data points from 3 indepen-
dent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way
ANOVA and Bonferroni post-hoc test) as compared to the corre-
sponding untreated CRC-SCs. Representative images are in Supple-
mentary Fig. S6c. d Dynamics of the acquisition of resistance in
SENSHIGH-CRC-SCs and SENSMED-CRC-SCs exposed to multiple
rounds of CHK1i treatment using the protocol of Fig. 1a. CRC-SCs
were considered resistant when they became insensitive to 200 nM
CHK1i (dotted line: threshold). See also Supplementary Fig. S6e.
e One representative SENS-CRC-SCs (#16SENS) was left untreated or
subjected to consecutive rounds of treatments as in a. Representative
images as well as quantitative data of the percentage of viable cells at
each round of treatment(s) or at the last time point are shown. Data are
expressed as means ± SEM of 3 independent experiments. Individual
data points are also shown for the last time point. The three individual
experiments are reported in Supplementary Fig. S6f. Data are analyzed
as in a. f Cell viability of some neoR-CRC-SCs reported in panel
d exposed for 96 h to CHK1i and/or TZ as indicated. Results are
expressed as means ± SEM and individual data point from 4 inde-
pendent experiments (on the left, with the exception of the 750 nM TZ-
treated conditions in which is 3) and 7 independent experiments (on
the right). Data on the right are pooled (#3+#6+#29neoR), while, on
the left, results for #30neoR are reported. *P < 0.05, **P < 0.01, ***P <
0.001 (one-way ANOVA and Bonferroni or Dunnett T3 post-hoc test)
as indicated. All significant P values are shown in Supplementary
Table S4. Supplementary figures associated: Supplementary Fig. S6.
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Aldrich (Millipore-Sigma, Merck group, St. Louis, MO),
and plasticware by Corning Life Sciences (Corning, NY)
and Thermo Scientific. Patient samples were obtained in
accordance with the standards of the institutional Ethics
Committee on human experimentation (authorization no.
CE5ISS09/282). CRC-SCs were isolated from these
samples and cultured as detailed in [21, 72], and were all
authenticated and validated for their in vivo stemness/self-
renewal potential upon xenotransplanted into immuno-
compromised mice as reported in [73]. Cells were routinely
confirmed to be Mycoplasma-free by PCR. CRC-SCs were
routinely maintained in Dulbecco’s Modified Eagle
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Medium (DMEM)/F12-based (#52100047, #21700018)
culture medium specific for CSCs containing 4 mg/mL
bovine serum albumin (BSA; #A1312, US Biological,
Salem, MA), 1X Penicillin-Streptomycin-Amphotericin B
(PSF; #17-745E, Lonza, Basel, Switzerland), 0.13%
NaHCO3 (#25080094, Thermo Scientific), 6 mM Hepes
(#15630056, Thermo Scientific), 2mM L-glutamine
(#25030024, Thermo Scientific), 0.1 mg/mL apotransferrin
(#T2252), 0.4 units heparin sodium salt (#H3393), 1.1%
glucose (#G8769), 25 µg/mL insulin (#91077 C), 6.3 ng/mL
progesterone (#P8783), 9.7 µg/mL putrescine dihy-
drochloride (#P5780), and 5.2 ng/mL sodium selenite
(#S5261) and supplemented with 20 ng/mL human epi-
dermal growth factor (EGF; #AF-100-15, PeproTech,
London, UK), 10 ng/mL human basic fibroblast growth
factor (bFGF; #AF-100-18B, PeproTech), and 10 mM
nicotinamide (#N0636). All CRC-SCs including neo-
resistant (neoR) CRC-SCs (whose generation is described
in the next session) were passaged once/twice a week at
dilution 1:2 by mechanical dissociation, through a micro-
pipette, and/or enzymatic dissociation, by incubating them
for less than 5 min at 37 °C with TrypLE™ Select 10X
(#A1217701, Thermo Scientific) and Accumax (#A7089)
(1:1, V:V), and incubated in standard culture conditions in
ultra-low attachment tissue culture flasks. In the experi-
ments, cells were seeded as single cells onto the appropriate
supports (6-, 24- or 96-well plates) 24 h before being sub-
jected to treatment.
Chemicals
The following compounds were provided by Selleck Che-
micals (Houston, TX): 5-fluorouracil (#S1209), adavosertib
(#S1525), B02 (#S8434), berzosertib (#S7102), camptho-
tecin (#S1288), cisplatin (#S1166), etoposide (#S1225),
gemcitabine (#S1714), GSK'872 (#S8465), hydroxyurea
(#S1896), irinotecan (#S2217), KU-55933 (#S1092), KU-
60019 (#S1570), mirin (#S8096), nocodazole (#S2775),
NU7026 (#S2893), olaparib (#S1060), oxaliplatin
(#S1224), prexasertib (#S7178), Q-VD-Oph
(#S7311), rabusertib (#S2626), rucaparib (#S1098), tala-
zoparib (#S7048), triapine (#S7470), UPF 1069 (#S8038)
VE-821 (#S8007), and veliparib (#S1004). Verapamil
(#V4629) were provided by Sigma-Aldrich, CCT241533
(#HY-14715B) by MedChem Express (Monmouth Junc-
tion, NJ), NP-004255 (#PC-61922) by ProbeChem
(Shanghai, China), and PV1019 (#220488) by Calbiochem-
Merck-Millipore (Billerica, MA). The appropriate amount
of DMSO (#5879) was employed for negative control
conditions.
Protocol for the generation of neo-resistant (neoR)
CRC-SCs
To stimulate the development of resistance to prexasertib
(CHK1i), we selected multiple CRC-SCs from our panel
previously characterized as sensitive to CHK1i, namely the
hypersensitive (or highly sensitive, SENSHIGH) CRC-SCs
Fig. 7 MRE11 and RAD51 cooperation contributes to RSR and
mitosis and is essential in PARP1-upregulating CRC-SCs. a, b Cell
viability (assessed by CellTiter-Glo® assay) and clonogenic survival of
neoR-CRC-SCs left untreated or exposed to inhibitors of MRE11
(mirin, MRE11i) and/or RAD51 (B02, RAD51i) for 72 h (b) or 96 h
(a) as indicated. Data are reported as means ± SEM from 5 (a) or 3 (b)
independent experiments. In b, representative images and individual
data points are also shown (dose range: #19neoR: 15 µM MRE11i, 2.5
µM RAD51i). *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA
and Bonferroni post-hoc test), as indicated. See also Supplementary
Fig. S7a–c. c Cell viability (assessed by CellTiter-Glo® assay) of innR-
CRC-SCs left untreated or exposed to inhibitors of MRE11 (mirin,
MRE11i) and/or RAD51 (B02, RAD51i) or 96 h as indicated. Data are
reported as means ± SEM from 9 independent experiments for all
conditions with the exception of RAD51i 2.5 µM in which 5 inde-
pendent experiments were performed. *P < 0.05, **P < 0.01, ***P <
0.001 (one-way ANOVA and Bonferroni or Dunnett T3 post-hoc test),
as indicated. See also Supplementary Fig. S7d, e. d–f Flow cytometry
and western-blot analyses of RSR functionality in representative neoR-
CRC-SCs either treated with 1 mM hydroxyurea (HU) and, after drug
washout, with 1 µM nocodazole (N) alone or together with MRE11i
and/or RAD51i (the HU+N assay, see Fig. 2a) (d; #1neoR), or
treated 24 h only with MRE11i and/or RAD51i (e; #1neoR; f;
#19neoR). In d and f, cell cycle profiles (mitotic (pH3+) cells are in
red) and quantification of S-phase or G2/M-phase or mitotic cells are
represented. Results are reported as means ± SEM from 5 independent
experiments (d) or as means ± SEM and individual data points from 4
independent experiments (f). *P < 0.05, **P < 0.01, ***P < 0.001 (one-
way ANOVA and Bonferroni or Dunnett T3 post-hoc test) as depicted
(d) or as compared to control condition (f). In e, antibodies recog-
nizing γH2AX, pRPA32 and/or RPA32 and/or nucleolin (as loading
control) were used. See also Supplementary Fig. S7f, g. g Immuno-
fluorescence analysis in neoR-CRC-SCs treated with MRE11i and/or
RAD51i for 24 h and then costained with antibodies against the
spindle assembly checkpoint (SAC) activation marker BUBR1 (in red)
and the mitotic marker pH3 (in green). Representative aberrant
metaphases activating the SAC and the anaphase ratio (i.e., of the
fraction of anaphases on 100 prophases+metaphases+anaphases, see
Materials and Methods) are reported. Results are means ± SEM from 6
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way
ANOVA and Dunnett T3 post-hoc test) as compared to control con-
dition. h Immunofluorescence analysis in neoR-CRC-SCs treated with
MRE11i and/or RAD51i for 48 h and then stained with an anti-cleaved
caspase-3 (CASP3A) antibody. Representative images and the quan-
tification of CASP3A+ cells are shown. Results are expressed as
means ± SEM and individual data points from 3 independent experi-
ments. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA and
Bonferroni post-hoc test) as indicated. i Proposed model. CRC-SCs
resistant to therapeutically-relevant replication poisons or ATR-CHK1
inhibitors display low levels of RS and PARP1 upregulation and can
be efficiently targeted by the combined inhibition of (i) CHK1+
PARP1, which provokes fork degradation and severe RS, resulting in
lethal replication catastrophe, or (ii) RAD51+MRE11, which
deregulates RSR and mitosis, resulting in cell death via mitotic cata-
strophe. Dose range in d–g: #1neoR: 25 µM MRE11i, 7.5 µM
RAD51i; #19neoR: 20 µM MRE11i, 5–7.5 µM RAD51i. All sig-
nificant P values are shown in Supplementary Table S4. Supplemen-
tary figures associated: Supplementary Figs. S7 and S8.
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#1 (Figs. 1–7), #16, #18, and #30 (Figs. 5c and 6d, e) and
the moderately sensitive (or medium-sensitive, SENSMED)
CRC-SCs #19 (Figs. 1–7), #3, #6, and #29 (Figs. 5c and
6d). For further details on the genetic and cytogenetic
background of CRC-SCs of our panel and for the classifi-
cation of CHK1i sensitivity and the IC50 values of CHK1i,
see [21] and Supplementary Fig. S1a. In these cells, CHK1i
resistance was induced as follow. CRC-SCs were dis-
sociated as single cells and then cultured for 24 h in T75-
flask and treated with CHK1i, starting from their IC50/
2 value concentration (i.e., 5 nM for #1 and 29 nM for #19)
to promote resistance to CHK1i. After 72 h, cells were
washed with PBS and cultured in fresh medium for at least
72 h. Several rounds of CHK1i administration were per-
formed according to the response of cells to each treatment,
using increasing concentrations of CHK1i until reaching the
dose of 1 μM. In experiments aimed at analyzing the effect
of PARP1i in preventing the acquisition of CHK1i resis-
tance (Fig. 6), SENS-CRC-SCs were subjected to the same
protocol of CHK1i administration also adding PARP1i at
varying doses according to their relative sensitivity (dose
range for olaparib: 2–7 µM (#1SENS and #19SENS) and
1–3 µM (#16SENS); dose range for talazoparib: 0.1–0.3 µM
(#1SENS and #19SENS) and 0.05–0.1 µM (#16SENS)).
For each 1-week treatment round, after 72h-of treatment
cells were dissociated as single cells and viable cells
counted upon staining with Trypan Blue (#15250061,
Thermo Scientific). In all experiments of neoR generation,
no more than one round of 72h-treatment per week was
performed to allow CRC-SCs to recover after each treat-
ment. For insights on the two sets of #1neoR-CRC-SCs
(#1neoRa and #1neoRb) reported in Fig. 2e and Supple-
mentary Fig. S4a see the Immunoblotting section.
Measurement of cell proliferation/viability,
generation of the drug sensitivity heatmap and
analysis of drug synergisms
To determine the impact of single drugs or drug combina-
tions on cell proliferation and survival, CRC-SCs dis-
sociated at single cells were seeded in 96-well plates (100
µL of medium/well) at a density of 6 × 103 cells/well. CRC-
SCs were then cultured for 24 h in drug-free medium and
left untreated or treated according to specific experimenta-
tions, as indicated in each figure and/or figure legend. Upon
72 h or 96 h from (co)treatment, cell viability/proliferation
was measured by the CellTiter-Glo® Luminescent Cell
Viability Assay (#G7572, Promega, Madison, WI) based on
luminescence counting of ATP levels by a multimode
reader (DTX-880; Beckman Coulter, Brea, CA), according
to the manufacturer’s instructions. All experiments were
performed in triplicate parallel instances and the means of
the triplicate (or duplicate in case of technical problems
with one replicate, which were excluded from the analysis)
were used for data representation (see Statistical proce-
dures). The heatmap in Fig. 1e illustrates the log2 values of
the ratio of percentage of viable neoR-CRC-SCs vs. viable
SENS-CRC-SCs (neoR/SENS) upon drug administration
calculated for each indicated dose using data from dose-
response viability curves reported in Fig. 1 and Supple-
mentary Figs. S1 and S2. Drug sensitivity heatmap was
generated using the “R” software (R Foundation for Sta-
tistical Computing, Vienna, Austria; http://www.R-project.
org/) and the following packages: ‘tcltk’, ‘tidyverse’,
‘readxl’, “ComplexHeatmap”, ‘reshape2’, and ‘data.table’.
The scale of the heatmap is from −3 (green; meaning that
SENS-CRC-SCs are more resistant than neoR-CRC-SCs) to
3 (red; meaning that neoR-CRC-SCs are more resistant than
SENS-CRC-SCs). To improve heatmap readability and
allow ratio calculation we applied the following changes.
First, the percentage of viable cells used to calculate log2
ratio values was arbitrarily set to “1” in the following
conditions in which this value was “0”: (i) 50 µM rabusertib
and 50 µM CCT241533 for #1neoR; (ii) 50 µM rabusertib
and 50 µM CCT241533 for #19SENS; and (iii) 50 µM
rabusertib and 50 µM CCT241533 for #19neoR (see Fig. 1;
Supplementary Fig. S1; Supplementary Table S2). Second,
to generate the heatmap, the log2 value (#1neoR/#1SENS)
of 12.5 µM and 50 µM berzosertib was set to the maximum
value “3” (Supplementary Table S2). To calculate the
synergistic drug effects in killing CRC-SCs, dose-response
data were analyzed on the basis of the Loewe additivity
model and visualized as a dose-response surface using the
Combenefit software [74] (see also https://sourceforge.net/
projects/combenefit/). In figures reporting the synergism, a
multicolor code was used to easily identified drug combi-
nation effects, with synergy and antagonism depicted
respectively in blue and red. Results were confirmed with
the DrugComb Portal (https://drugcomb.fimm.fi/) also using
the Bliss independence (BLISS), Highest Single Agent
(HSA) and Zero interaction potency (ZIP) models. See [74]
and [75] for primary references and further insights on the
drug combination effect models employed.
Clonogenic assay
For clonogenic potential assessment, CRC-SCs cultured as
reported above were left untreated or exposed for 24 h
(Fig. 1c) or 72 h (Figs. 5a, 6c, and 7b; Supplementary Figs.
S5b, S6c, and S7c) to CHK1i, PARP1i, MRE11i (mirin)
and/or RAD51i (B02) (first round of treatment). Upon
treatment, CRC-SCs were washed (to remove the drug) and
dissociated at single cells. Upon resuspension in 0.3%
agarose (#50111, SeaPlaque GTG Agarose; Lonza), cells
were seeded, at least in duplicate, in 24-well plates at a
density of 500–1000 cells/well over a layer of 0.4% agarose.
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Experiments were always repeated at least in triplicate
independent instances. Cells were then cultured for soft agar
assays in drug-free CSC medium with the exception of
Supplementary Fig. S5b in which they were treated again
with specific drugs (second round of treament), and incu-
bated under standard culture conditions for up to 14 days as
reported in figure legends. Finally, samples were fixed/
stained with 0.02% crystal violet (#C0775) and colonies
counted. Only wells with countable colonies were con-
sidered in the analysis. The means of the replicates were
used for data representation of each independent experiment
(see Statistical procedures). For each CRC-SCs, repre-
sentative images were selected from one or more clonogenic
multi-well plates of the same experiment with similar results
and, upon selection and crop from the original image, single
wells were ordered in figure panels according to the fol-
lowing experimental conditions: control, 1st monotherapy,
2nd monotherapy, and combined therapy. Survival fractions
were calculated by normalizing the number of colonies in
treated conditions to the plating efficiency of untreated cells
(i.e., colony formation over control condition). In Supple-
mentary Fig. S5b quantification of colony formation for
cells cultivated in drug-free condition in the first round of
treatment (i.e., the first columns of the six group of two
columns reported in the histogram) are a pool of data
coming from 3 independent experiments some of which are
also used for quantifying the same parameters in Fig. 5a.
Only experiments including all experimental conditions are
used for the quantification reported in Fig. 5a.
Cytofluorometric studies
For the measurement of DNA content, γH2AX and/or pH3
levels (to assess DNA-damaged and mitotic cells, respec-
tively), ethanol-fixed samples were permeabilized with 0.25%
(v/v) Tween 20 (#P1379) in PBS at 4 °C for 15min and, upon
incubation in 3% (w/v) BSA in PBS for 30min at 4 °C (to
block unspecific binding), stained with a primary anti-γH2AX
(S139) (1:250; #05-636, Merck Millipore; RRID:
AB_309864) and/or a primary anti-pH3 (S10) (1:1500;
#3377, Cell Signaling Technology, Danvers, MA; RRID:
AB_1549592) in 1% (w/v) BSA in PBS overnight at 4 °C.
Samples were then co-stained for 30min at 4 °C with an
Alexa Fluor® 488-goat anti-mouse secondary antibody (#A-
21121; RRID:AB_141514) and/or an Alexa Fluor® 555-goat
or 647-donkey anti-rabbit secondary antibody (#A-21429;
RRID:AB_141761 or #A-31573; RRID:AB_2536183,
respectively) (both 1:500; Thermo Scientific) together with
10 µM DAPI (1mM; #D1306, Thermo Scientific) in 1% (w/
v) BSA in PBS. To assess the impact of CHK1i on the
expression of surface colorectal-CSC markers, 3×105 cells
seeded in 6-well plates (2 mL of medium/well) were cultured
for 24 h, and then left untreated or exposed to 100 or 500 nM
CHK1i. Upon 24 h or 48 h from treatment, cells were resus-
pended at 8 × 105/mL, seeded in 96-well plates (100 µL of
medium/well) and stained with a CD44v6-purified antibody
(diluted 1:20 in CSC culture medium; #BBA13, R&D Sys-
tems, Minneapolis, MN; RRID:AB_356935). Samples were
incubated in the dark and on ice for 30min and, upon two
washes with CSC culture medium, co-stained for 30min with
the appropriate Alexa Fluor® 488-goat anti-mouse secondary
antibody (1:500 in CSC culture medium). Cells were washed
twice and then pellets were resuspended in 100 μL CSC
culture medium supplemented with 1 µM DAPI. Cells were
incubated overnight at 4 °C upon flow cytometry-mediated
analyses. Cell cycle progression was assessed by cyto-
fluorimetry as previously described [76]. Cytofluorometric
acquisitions were performed by means of a BD FACSCan-
toTM II (BD Biosciences, BD, Franklin Lakes, NJ), a Gallios®
Flow Cytometer (Beckman Coulter, Indianapolis, IN) or a
MACSQuant® Analyzer 10 (Miltenyi Biotec, Bergisch Glad-
bach, Germany) while data were statistically evaluated using
the FlowJo software (FlowJo LLC, BD; RRID:
SCR_008520). Only the events characterized by normal for-
ward scatter (FSC) and side scatter (SSC) parameters were
gated for inclusion in the statistical analysis. Surface
colorectal-CSC markers were analyzed only on viable cells (i.
e., cells excluding DAPI). Cell cycle analyses were performed
upon gating on singlets and upon exclusion of the sub-G1.
Hydroxyurea-nocodazole (HU+ N) assay
To assess RSR functionality in basal conditions, we used a
pre-validated and approved protocol based on the admin-
istration of 1 mM hydroxyurea (HU) for 15 h followed by
drug washout and treatment with 1 µM nocodazole (N) for
24 h [42, 44, 45, 77]. In experiments aimed at analyzing the
role of CHK1, MRE11, PARP1, and/or RAD51 on RSR
functionality (Figs. 2b, 3c, and 7d; Supplementary Figs.
S3a, S3b, and S4b), HU-treated CRC-SCs were washed and
administered for 24 h with nocodazole together with inhi-
bitors of CHK1 (100 nM CHK1i), MRE11 (20 µM mirin),
PARP1 (500 nM talazoparib) and/or RAD51 (5 µM B02). In
all cases, samples were recollected, fixed with ethanol and
stained with the DNA dye DAPI together with an antibody
directed against pH3 (S10) (1:1500; #3377) and/or γH2AX
(1:250; #05-636) prior to cycle profiling analyses by flow
cytometry as reported in the Cytofluorometric studies sec-
tion. For the interpretation of the HU+N assay, the pre-
sence of a functional RSR allows cells to resolve RS
induced by HU, and this results in DNA replication restart,
S-phase progression and metaphase (and thus not S-phase)
arrest when cells are challenged with nocodazole. On the
contrary, cells with impaired RSR display an S-phase arrest,
as shown by an increase in the fraction of cells with a DNA
content between 2n and 4n in cell cycle profiles. This is due
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to the accumulation of ssDNA from unresolved RS, whose
entity depends on the severity of RSR impairment. Note
that the quantification of the percentage of S-phase, G2/M-
phase and pH3+ cells in Supplementary Fig. S3a and of
γH2AX+ cells among G2/M-phase in Supplementary Fig.
S3b for #1SENS-CRC-SCs and #1neoR-CRC-SCs sub-
jected to the HU+N protocol includes data from at least 4
independent experiments of which some are used for
quantifying the same parameters in Figs. 3c and 7d. Only
experiments including all experimental conditions are used
for the quantification reported in Figs. 3c and 7d.
Immunofluorescence
The immunofluorescence detection of DNA damage mar-
kers and SAC activation was performed as follow. Briefly,
dissociated CRC-SCs were fixed in 4% (w/v) paraf-
ormaldehyde (PFA; #28908, Thermo Scientific) in PBS and
deposited on poly-D-lysine-coated (#P7886) glass slides.
Slides were air-dried and then permeabilized for 15 min
with 0.1% (v/v) Triton X-100 (Amersham Biosciences; GE
Healthcare Life Sciences, Little Chalfont, UK) in PBS.
Samples were then incubated for 30 min in 5% (w/v) BSA
in PBS and immunostained overnight at 4 °C or 2 h at RT
with the following primary antibodies (diluted as indicated):
bromodeoxyuridine (BrdU, 1:25; #347580; RRID:
AB_400326), BUBR1 (1:50; #612502; RRID:AB_399803)
(both from BD Biosciences), cleaved caspase-3 (1:400;
#9661, Cell Signaling Technology; RRID:AB_2341188),
rabbit γH2AX (S139) (1:400; #9718, Cell Signaling Tech-
nology; RRID:AB_2118009), mouse γH2AX (S139)
(1:250; #05-636), pH3 (S10) (1:1500; #3377), pRPA32 (S4/
S8) (1:250; #A300-245A, Bethyl Laboratories; RRID:
AB_210547). The slides were finally incubated with the
appropriate Alexa Fluor conjugates (1:600) and 10 µM
Hoechst 33342 (to counterstain nuclei, #H1399) (both from
Thermo Scientific). Fluorescence images were captured
using a Leica DMR fluorescence microscope equipped with
a 100X oil immersion objective and the Leica QWin soft-
ware or a Leica DMI3000 B fluorescence microscope
equipped with a 40X objective, Leica DFC 310FX camera
and LAS X software (Leica Microsystems, Wetzlar, Ger-
many). Analysis was performed directly by microscopy on
100 cells per condition and/or using Adobe Photoshop CC
2015 (Adobe, San Jose, CA; RRID:SCR_014199) and
ImageJ v1.8 software (National Institute of Health,
Bethesda, MD; http://rsb.info.nih.gov/ij/; RRID:
SCR_003070). Cells were considered positive for γH2AX,
pRPA32 and ssDNA when they display more than 5 visible/
overlapping foci (Figs. 2d and 3g; Supplementary Fig. S4c).
Note that in Fig. 2d the quantification of the percentage of
pRPA32+ cells for neoR-CRC-SCs left untreated or treated
with CHK1i includes data from at least 3 independent
experiments of which some are used for quantifying the
same parameters in Supplementary Fig. S4c. Spindle
assembly checkpoint activation was assessed by evaluating
nuclear/kinetochore localization of BUBR1 in metaphase
cells (i.e., positive for pH3, pH3+) (Fig. 7g). The anaphase
ratio reported in Fig. 7g was calculated by counting the
fraction of anaphases on 100 prophases+metaphases+ana-
phases according to their classic morphology (via Hoechst
33342 staining) or pH3 positivity (prophases and meta-
phases: pH3+; anaphases: pH3−). To assess apoptosis
induction, CRC-SCs were resuspended in 90% CSC culture
medium/10% Matrigel Basement Membrane Matrix
(#354230, Corning) to a final concentration of 3.5 × 105
cells in 500 µL, and then seeded in 24-well plates. Upon 24
h, CRC-SCs were left untreated or exposed for 48 h to
MRE11i and/or RAD51i alone or in combination with Q-
VD-Oph or GSK’872. Finally, the cells were stained with 1
µg/mL propidium iodide (PI, a vital dye; #P3566, Thermo
Scientific) and 8 µM Hoechst 33342 and analyzed by live
fluorescence microscopy. Images were captured using a
Leica DMI3000 B fluorescence microscope equipped with a
20X objective, Leica DFC 310FX camera and LAS X
software (Leica Microsystems). Representative images of at
least two independent experiments with similar results are
reported in Supplementary Fig. 8.
Immunoblotting
The detection of protein levels was performed as previously
reported [21]. Briefly, CRC-SCs were harvested, washed
with PBS, and lysed for 30 min on ice with a buffer con-
taining T-PER reagent (#78510, Thermo Scientific), 300
mM NaCl (#31434), and protease/phosphatase inhibitors
cocktails (#P8340, #P5726, #P0044). Samples were then
centrifuged for 15 min at 13000 rpm, and supernatants
collected. Total protein concentration was determined by
the Bradford reagent method (Bio-Rad Protein Assay,
#5000002, Bio-Rad). Equal amounts of proteins (30 μg)
were resolved by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and electro-transferred to a nitrocellulose
membrane (#88018, Pierce-Thermo Scientific). Membranes
were incubated overnight with the primary antibody of
interest and then for 1 h at RT with the appropriate horse-
radish peroxidase-conjugate secondary antibody (sheep
anti-mouse IgG whole antibody, #GENA931; RRID:
AB_772210; donkey anti-rabbit IgG whole antibody,
#GENA934; RRID:AB_2722659 or AB_772206; or mouse
anti-goat IgG whole antibody, #sc-2354, Santa Cruz Bio-
technology, Dallas, TX; RRID:AB_628490). Chemilumi-
nescence 16-bit imaging was performed with the Kodak
Image Station 4000R (IS4000R; Eastman Kodak Company,
Rochester, NY) and the Carestream Molecular Imaging
Software version 5.0 (Carestream Health, Rochester, NY),
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or with the G:Box Chemi-XX9 and GeneSys Software
v1.5.6 (Synoptics, Cambridge, UK; RRID:SCR_015770).
The following primary antibodies were used (diluted as
indicated): pATM (S1981) (1:1000; #ab81292; RRID:
AB_1640207), ATM (1:500; #ab78; RRID:AB_306089)
(both from Abcam, Cambridge, UK), pCHK1 (S317)
(1:1000; #12302; RRID:AB_2783865), CHK1 (1:750;
#2345; RRID:AB_10693648), rabbit γH2AX (S139)
(1:1000; #9718), PARP1 (1:1000; #9542; RRID:
AB_2160739) (all from Cell Signaling Technology),
pRPA32 (S4/S8) (1:1000; #A300-245A; RRID:
AB_210547), and RPA32 (1:1000; #A303-874A; RRID:
AB_2620224) (both from Bethyl Laboratories, Mon-
tgomery, TX). Anti-β-Actin (1:1000; #4967, Cell Signaling
Technology; RRID:AB_330288), anti-C23/Nucleolin
(1:1000; #sc-8031, Santa Cruz Biotechnology; RRID:
AB_670271), anti-Cofilin (1:1000; #3318, Cell Signaling
Technology; RRID: AB_2080595) or anti-β-Tubulin
(1:1000; #T4026; RRID:AB_477577) antibodies were used
to monitor equal loading of lanes. Representative western-
blot images of at least two independent experiments with
similar results are reported in figures, with the exception of
Fig. 2e and Supplementary Fig. S4a in which one western-
blot was performed. Indeed, in these figures, #1neoRa and
#1neoRb correspond to cells recollected at different times
during the protocol of generation of resistance to CHK1i,
which last some months reducing the possibility to have
replicates. Specifically: #1neoRa after 12 weeks and
#1neoRb after 17 weeks from the first round of CHK1i
administration. Of note, #1neoRb display higher resistance
to CHK1i than #1neoRa.
Deep DNA sequencing
For deep DNA sequencing targeting of genes involved in
the DDR (see Supplementary Table S3), we designed a
custom panel using the QIAseq Targeted DNA Custom
Panel Builder (Qiagen, Hilden, Germany). The libraries
were prepared with 40 ng genomic DNA using the QIAseq
targeted DNA technology following the manufacturer’s
instructions. The resulting libraries were sequenced on an
Illumina NextSeq 500 (Illumina, San Diego, CA) in paired-
end mode, sequencing from each side 150 bp. FASTQ files
were analyzed with CLC Genomics Workbench software
(v12.0, Qiagen). The QIASeq Panel analysis was set on
Somatic mode for Illumina reads. Variant annotation was
carried out with Annovar (version update at July 2018) [78].
Only somatic variants with Allele Frequency>10, cover-
age>100x, Protein Damaging consequence, and dbSNP
MAF < 5% were kept. Germline pathogenic variants were
annotated with ClinVar [79] and pathogenicity of BRCA*
variants was annotated via the BRCA Exchange database
(https://brcaexchange.org/) [80]. The Oncoprint (Fig. 3a)
was generated using custom R scripting and the Complex-
Heatmaps library available at https://github.com/jokergoo/
ComplexHeatmap. For the Oncoprint, mutations were fur-
ther filtered on the basis of the following criteria: (ì)
annotated as (likely) oncogenic in oncoKB database (https://
oncokb.org/) [81] and/or (ii) annotated on the COSMIC
database (http://cancer.sanger.ac.uk/cosmic) (see Supple-
mentary Table S3; Analysis performed in July 2019).
Sequencing data generated in the context of this study have
been deposited at European Genome-phenome Archive
under accession numbers EGAS00001004892.
DNA fiber assay
For DNA fiber length measurement, 4 × 105 CRC-SCs were
seeded as single cells in 6-well plates and, upon 24 h of
cultivation, left untreated or treated for 6 h with CHK1i
(100 and 200 nM for SENS-CRC-SCs and neoR-CRC-SCs,
respectively) and/or talazoparib (500 nM). DNA replication
sites were labeled with 250 µM 5-Iodo-2-deoxyuridine
(IdU; #I7125) 30 min prior to the end of treatments. Cells
were then washed with cold PBS and resuspended in
20–50 μl of cold PBS. DNA spreading was performed as
follow: 2.5 μl of each cell suspension was spotted at the end
of the microscope slide (SuperFrost slides; VWR interna-
tional, Radnor, PA) and air-dried for a few minutes.
Thereafter 7.5 μl of the lysis solution (200 mM Tris-HCl-
pH 7.5, 50 mM EDTA, 0.5% SDS in water) was applied on
top of the cell suspension, then mixed by gently stirring
with a pipette tip and incubated for 1 min 45 s. The slides
were tilted to 15° to allow the DNA fibers spreading along
the slide. The dried DNA fibers were then fixed in a
methanol/acetic acid (3:1) solution for 10 min, washed in
dH2O, and denaturated in 2.5 M HCl for 80 min. Labeled
DNA fiber immunodetection was performed via sequential
incubation of the slides for 20 min with a blocking solution
(5% BSA in PBS), for 2 h at RT with a primary antibody
solution (anti-BrdU diluted 1:25), and for 1 h at RT with
the appropriate secondary antibody solution. Images were
acquired randomly from fields with untangled fibers using
the Eclipse 80i Nikon Fluorescence Microscope (Nikon,
Minato-ku, Tokyo, Japan), equipped with a VideoConfocal
(ViCo) system (Nikon). Labeled tract lengths were mea-
sured using ImageJ v1.8 software. A minimum of 191
DNA fibers pooled from two or four independent experi-
ments were analyzed for each experimental condition. Only
well-isolated DNA fibers were considered in the analysis.
In Fig. 3f, the dot plot on the left (track length comparison
between untreated SENS-CRC-SCs vs. untreated neoR-
CRC-SCs) reports data pooled from four experiments,
including two experiments which are also reported in the
dot plots concerning SENS-CRC-SCs (in the center) and
neoR-CRC-SCs (on the right).
G. Manic et al.
Detection of single-stranded DNA by native IdU
assay
To detect nascent ssDNA, 3 × 105 CRC-SCs were seeded as
single cells in 6-well plates and, upon 24 h cultivation, were
either left treated or treated with specific pharmacological
inhibitors. Finally, cells were administrated with 250 µM IdU
for 30 min before the end of treatments as reported in [49].
Alternatively, to detect parental ssDNA, upon 24 h cultiva-
tion, seeded cells were administrated with 10 µM IdU for 24 h
as indicated in [49]. IdU-stained cells were then left untreated
or exposed to CHK1i (200 nM), and/or talazoparib (500 nM)
for 6 h. In both protocols, cells were dissociated and fixed
with 4% PFA. Finally, nascent/parental ssDNA was immu-
nodetected by using a primary antibody directed against
BrdU, as described in the Immunofluorescence section.
Quantitative nascent DNA analyses were performed on ≥12
randomly selected images. Briefly, blue nuclear fluorescence
was used to identify nuclear regions on which green intensity
(nascent DNA) means were quantified. All steps were per-
formed using ImageJ v1.8 software. A minimum of 509 cells
per condition pooled from two independent experiments were
analyzed. Quantitative parental DNA analyses was performed
as reported in Immunofluorescence section.
In vivo study
In vivo studies are all included in an experimental protocol
approved by the Institutional Animal Experimentation
Committee (authorization no. 08/2017-PR and 227/2016-
PR). Housing and handling of animals were in strict com-
pliance with national Animal Experimentation Guidelines
for Laboratory Animal Welfare (D.L.26/14) and in accor-
dance with the Directive EU63/2010. Female NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG; #005557; RRID:
IMSR_JAX:005557) mice of 4–6-week-old (~21 g) were
provided from The Jackson Laboratory (Bar Harbor, ME).
Animals were always employed after an acclimatization
period of 14 days and left under ad libitum feeding and
drinking conditions. For mice engraftment, CRC-SCs were
resuspended in 50% CSC culture medium/50% Matrigel
Basement Membrane Matrix to a final concentration of 5 ×
106 cells/mL, and then 5 × 105 cells were injected sub-
cutaneously in the flank of mice. Tumors were measured
twice a week by a common caliper. When tumors were
palpable (i.e., ~14 mm3, 2–3 weeks from the inocolum),
mice were randomly allocated to the following treatment
groups: Control (vehicles), CHK1i-treated, olaparib-treated
and CHK1i+ olaparib co-treated groups. No blinding was
performed. In more detail, CHK1i dissolved in 50% H2O
and 50% of a solution of 40% Cyclodextrin (#OC15979,
Carbosynth, Compton, UK) was administered at a dose of
5 mg/kg for three cycles of 1-week consisting of three
consecutive days, bis in die, followed by 2 days of rest +
1 day of treatment (bis in die) and one day of rest, while
olaparib dissolved in 11,6% DMSO+ 25% of a solution of
40% Cyclodextrin + 63.4% PBS was administered at a dose
of 50 mg/kg for three cycles of three consecutive days, once
a day, followed by 2 days of rest + 1 day of treatment (once
a day) and one day of rest. To calculate tumor volumes, we
used the modified ellipsoidal formula: V= (length ×
width2)/2. At least 7 mice per group were employed (see
Statistical procedures). Outliers or mice with symptoms non
attributable to cancer were excluded as a predetermined
criterion. Animals were euthanized according to the national
Animal Welfare Guidelines. See [21] for further details.
Statistical procedures
For in vitro experiments, no statistical methods were used to
determine sample size. In vitro experiments were indepen-
dently repeated at least three times with similar results, with
the exception of few cases in which experiments were
repeated less than three times (always specified in figure
legends and/or in specific Materials and Methods sections).
In case of lack of clarity or conclusiveness in statistical sub-
significant trends, sample number was increased to more
than 3 to improve statistical power. In in vivo experiments,
sample size was determined as follows. Considering as
outcome of interest the reduction of tumor growth upon
treatment, we hypothesized that 1% of tumors in the group
of mice treated with the vehicle and 70% of tumors in the
group of mice treated with PARP1i+ CHK1i display a
decrease in their in vivo growth. Applying a one-sided
Fisher’s Exact test and considering a statistical power equal
to 80% and a significance level of 0.05, we used at least 7
mice for all groups. The exact sample size (n) for each
experimental group/condition, whether the samples repre-
sent technical or biological replicates, the number of repli-
cates in individual experiments, and data/replicate exclusion
criteria are reported in figure legends or in the specific
Materials and Methods section. Data were analyzed with
Microsoft Excel (Microsoft, Redmond, WA) or Prism
(v8.3.0, GraphPad Software, San Diego, CA), while statis-
tical analyses were carried out using Prism and SPSS
software (SPSS v.21, SPSS Inc-IBM, Chicago, IL). For
each set of data of each in vitro experiment conducted at
least in three independent instances, normal distribution was
controlled with the Shapiro–Wilk test using SPSS and/or
Prism. In case of data with a normal distribution, statistical
analysis was performed as follow. For comparisons invol-
ving only two groups of samples, statistical significance was
evaluated by unpaired t-test or Welch’s unpaired t-test,
depending on variance equality between the two groups
(compared using the F-test). For comparisons involving
more than two groups of samples, statistical significance
Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of. . .
was evaluated by ordinary one-way ANOVA followed by
Bonferroni post-hoc test or by Brown–Forsythe and Welch
one-way ANOVA followed by Dunnett T3 post-hoc test
depending on variance equality (assessed using the
Brown–Forsythe test). Alternatively, in case of data not
normally distributed or of two independent experiments,
Mann−Whitney test or Kruskal−Wallis test followed by
Dunn’s post-hoc test was applied. Statistical significance on
in vivo growth curves was assessed by two-way ANOVA
followed by Bonferroni post-hoc test. For the last time
point, statical significance of tumor growth variation was
evaluated with Kruskal−Wallis test followed by Dunn’s
post-hoc test. In the dose-response curves of Fig. 1, statis-
tical analysis was not performed in few conditions in which,
in at least one CRC-SCs, a very low percentages of cells
(less than 2%, mean of ≥3 independent experiments) sur-
vived the treatment, as for the highest concentration(s)
of berzosertib (12.5 and 50 µM), camptothecin (12.5 and
50 µM), prexasertib (50 µM) and rabusertib (50 µM). Sta-
tistical analysis for γH2AX+ S-phase or G2/M-phase cells
was not performed given the low percentage (≤3%) of
positive cells (Supplementary Fig. S7g). We considered
statistically significant P values less than 0.05. All sig-
nificant P values are reported in Supplementary Table S4. In
in vitro experiments involving normalization of treated on
untreated conditions, controls are expressed as percen-
tages ± SEM calculated upon normalization on the average
of raw control data of all experiments included in each
analysis. In experiments with small sample sizes (n < 5),
individual data points from independent experiments are
represented as single dots either in box-plots in which
also the mean is illustrated or in columns representing
mean ± SEM. For figure readability, experimental data of
dose-response curves of Fig. 1b and 1c are shown as
mean ± SEM, while individual experiments for each drug
treatment are reported in Supplementary Figs. S1c and S1e.
Likewise, in Fig. 6a and 6e, data are reported as mean ±
SEM calculated from the individual experiments illustrated
in Supplementary Figs. S6b and S6f, with SEM for control
condition calculated as described above and statistical
analysis performed only for the last time point.
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